125 related articles for article (PubMed ID: 28862075)
1. Shedding light on designing potential meprin β inhibitors through ligand-based robust validated computational approaches: A proposal to chemists!
Adhikari N; Amin SA; Ghosh B; Jha T
J Biomol Struct Dyn; 2018 Aug; 36(11):3003-3022. PubMed ID: 28862075
[TBL] [Abstract][Full Text] [Related]
2. A combined ligand-based and structure-based
Jana S; Banerjee S; Baidya SK; Ghosh B; Jha T; Adhikari N
J Biomol Struct Dyn; 2024 Jan; ():1-17. PubMed ID: 38165455
[TBL] [Abstract][Full Text] [Related]
3. Structural refinement and prediction of potential CCR2 antagonists through validated multi-QSAR modeling studies.
Amin SA; Adhikari N; Baidya SK; Gayen S; Jha T
J Biomol Struct Dyn; 2019 Jan; 37(1):75-94. PubMed ID: 29251559
[TBL] [Abstract][Full Text] [Related]
4. Structure-Guided Design, Synthesis, and Characterization of Next-Generation Meprin β Inhibitors.
Ramsbeck D; Hamann A; Richter G; Schlenzig D; Geissler S; Nykiel V; Cynis H; Schilling S; Buchholz M
J Med Chem; 2018 May; 61(10):4578-4592. PubMed ID: 29694039
[TBL] [Abstract][Full Text] [Related]
5. First insight into structure-activity relationships of selective meprin β inhibitors.
Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
[TBL] [Abstract][Full Text] [Related]
6. An integrated
Dholey Y; Chaudhuri A; Sen Chakraborty S
J Biomol Struct Dyn; 2020 Apr; 38(7):2080-2092. PubMed ID: 31184526
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling coupled with molecular dynamic simulation approach to identify new leads for meprin-β metalloprotease.
Chaudhuri A; Hudait N; Chakraborty SS
Comput Biol Chem; 2019 Jun; 80():292-306. PubMed ID: 31054542
[TBL] [Abstract][Full Text] [Related]
8. The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis.
Broder C; Becker-Pauly C
Biochem J; 2013 Mar; 450(2):253-64. PubMed ID: 23410038
[TBL] [Abstract][Full Text] [Related]
9. Structure and Dynamics of Meprin β in Complex with a Hydroxamate-Based Inhibitor.
Linnert M; Fritz C; Jäger C; Schlenzig D; Ramsbeck D; Kleinschmidt M; Wermann M; Demuth HU; Parthier C; Schilling S
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073350
[TBL] [Abstract][Full Text] [Related]
10. Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin α and β.
Madoux F; Tredup C; Spicer TP; Scampavia L; Chase PS; Hodder PS; Fields GB; Becker-Pauly C; Minond D
Biopolymers; 2014 Sep; 102(5):396-406. PubMed ID: 25048711
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of pyrazole-based inhibitors of meprin α and β.
Tan K; Jäger C; Geissler S; Schlenzig D; Buchholz M; Ramsbeck D
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2165648. PubMed ID: 36661029
[TBL] [Abstract][Full Text] [Related]
12. Tertiary-Amine-Based Inhibitors of the Astacin Protease Meprin α.
Tan K; Jäger C; Schlenzig D; Schilling S; Buchholz M; Ramsbeck D
ChemMedChem; 2018 Aug; 13(16):1619-1624. PubMed ID: 29927060
[TBL] [Abstract][Full Text] [Related]
13. Meprin β induces activities of A disintegrin and metalloproteinases 9, 10, and 17 by specific prodomain cleavage.
Wichert R; Scharfenberg F; Colmorgen C; Koudelka T; Schwarz J; Wetzel S; Potempa B; Potempa J; Bartsch JW; Sagi I; Tholey A; Saftig P; Rose-John S; Becker-Pauly C
FASEB J; 2019 Nov; 33(11):11925-11940. PubMed ID: 31381863
[TBL] [Abstract][Full Text] [Related]
14. Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques.
Amin SA; Bhargava S; Adhikari N; Gayen S; Jha T
J Biomol Struct Dyn; 2018 Feb; 36(3):590-608. PubMed ID: 28132591
[TBL] [Abstract][Full Text] [Related]
15. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
16. Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.
Halder AK; Saha A; Jha T
J Pharm Pharmacol; 2013 Oct; 65(10):1541-54. PubMed ID: 24028622
[TBL] [Abstract][Full Text] [Related]
17. Meprin-β regulates production of pro-inflammatory factors via a disintegrin and metalloproteinase-10 (ADAM-10) dependent pathway in macrophages.
Li YJ; Fan YH; Tang J; Li JB; Yu CH
Int Immunopharmacol; 2014 Jan; 18(1):77-84. PubMed ID: 24239627
[TBL] [Abstract][Full Text] [Related]
18. Fetuin-A and cystatin C are endogenous inhibitors of human meprin metalloproteases.
Hedrich J; Lottaz D; Meyer K; Yiallouros I; Jahnen-Dechent W; Stöcker W; Becker-Pauly C
Biochemistry; 2010 Oct; 49(39):8599-607. PubMed ID: 20806899
[TBL] [Abstract][Full Text] [Related]
19. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A.
Herzog C; Haun RS; Ludwig A; Shah SV; Kaushal GP
J Biol Chem; 2014 May; 289(19):13308-22. PubMed ID: 24662289
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of Selective Inhibitors of Meprin α (Part II).
Wang C; Diez J; Park H; Spicer TP; Scampavia LD; Becker-Pauly C; Fields GB; Minond D; Bannister TD
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33673639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
